- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2019 | Daily Highlights
Gout treatment and renal outcome
THE ROLE OF A ‘TREAT-TO-TARGET’ APPROACH ON LONG-TERM RENAL OUTCOMES IN PATIENTS WITH GOUT
Abstract: 334
Authors: Woo-Joong Kim et al.
Key content:
This retrospective study evaluated the clinical importance of implementing the «treat-to-target» approach in the long-term management of gout in relation to renal function.
Out of 719 patients with gout 244 received urate-lowering-therapy (ULT) for more than 12 months. A serum uric acid (SUA) target concentration of < 6 mg/dl (360 mmol/l) was attained for 191 patients (78.3%). Improvement in renal function was only demonstrated in the subjects in whom the SUA target was achieved. A statistically significant difference in the mean change in eGFR with respect to SUA target achievement was apparently shown in individuals with chronic kidney disease (CKD) stage 3.
Relevance:
This study confirms that long-term SUA lowering below 6 mg/dl (360 mmol/l) after initiation of ULT is associated with significant improvement of renal function in patients with gout.
There is more and more increasing evidence that treat-to-target of gout reduces not only the risk of cardiovascular events but also improves kidney function.
Zusammenfassung und Kommentar von:
Dr. Thomas Langenegger
Zug
